H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) on September 9 and set a price target of $48.00. The company’s shares closed last Friday at $15.87.
According to TipRanks, Fein is an analyst with an average return of -8.2% and a 36.30% success rate. Fein covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, AC Immune SA, and Liquidia Technologies.
Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $43.00, representing a 170.95% upside. In a report released on September 8, Needham also maintained a Buy rating on the stock with a $38.00 price target.
See the top stocks recommended by analysts >>
Based on KalVista Pharmaceuticals’ latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $24.11 million. In comparison, last year the company had a GAAP net loss of $14.96 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
Read More on KALV:
- H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
- BTIG Keeps Their Hold Rating on Zscaler (ZS)
- Zymeworks (ZYME) Receives a Buy from SVB Securities
- SVB Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
- Analysts’ Top Utilities Picks: Devon Energy (DVN), CMS Energy (CMS)
